Answers are grounded in this paper and cite their sources.
Previous shortcomings of CD137-targeted immunotherapy may be overcome by engineered bispecific agents (Claus et al ., this issue).
No takes yet. Share an insight, caveat, or question.
Sanmamed et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: